Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

Trial Profile

Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2014

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Colorectal cancer; Neutropenia
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 09 Jun 2014 New trial record
    • 03 Jun 2014 Primary endpoint "infection rate"has been met.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top